Global Interventional Pulmonology Market Research Report 2021-2026 |Key Players, Growth Analysis, Share, Global Trends

Interventional pulmonologists use new techniques due to aerosol-producing procedures during a Coronavirus outbreak.

The coronavirus disease has raised the likelihood of human-to-human respiratory droplet transmission, combined with a high level of population mobility, resulting in the rapid global spread. The importance of healthcare institutions and stakeholders in the worldwide interventional pulmonology market has grown as a result of this. Interventional pulmonologists (IP) are at risk of infection due to the high number of active COVID-19 cases in Singapore, India, Canada, and Pakistan. To lessen the susceptibility of healthcare systems, firms in the interventional pulmonology market are establishing resilient supply chains of devices, drugs, catheters, and stents, among other things.

Bronchoscopy, like other open airway or aerosol-generating procedures, increases the danger of spreading contaminated droplets. To protect the safety of patients and other medical personnel, interventional pulmonologists are adjusting to such high-risk treatments. Because even after two doses of immunization, there remains a high risk of developing the novel virus, interventional pulmonologists and other value chain stakeholders are maintaining optimal medical services to optimize clinical outcomes.

Targeted Therapies and IP Workforce Collaboration Aid in Improving Medical Outcomes

By 2028, the interventional pulmonology market is expected to exceed $8 billion. A large amount of an IP's duties involves lung cancer diagnosis, staging, and pulmonary nodule care. Because lung cancer screening programs are becoming more popular in many parts of the world, IPs' workload is likely to expand in the future. The IP workforce, on the other hand, faces daily challenges in locating the peripheral pulmonary nodule and performing correct mediastinal staging. Stakeholders are focused on customized medicine, targeted medicines, and collaboration among IP, medical oncology, and pathology to ensure the patient's quality of life in order to overcome these issues.

Robotic Bronchoscopy Platforms Show Promise in Accurate Lung Cancer Diagnosis

In the interventional pulmonology sector, robotic bronchoscopy is becoming a major changer. This explains why the market is expected to grow at a rapid rate of 9% over the projected period. Companies are anticipated to work with researchers to develop new robotic bronchoscopy platforms that allow pulmonologists to view and access lung nodules without having to do invasive surgery.